Long-term outcomes of single stenting compared with double stenting strategy for unprotected left main coronary artery disease

A protocol for systematic review and meta-analysis

Jia-jie Wang, MD, Xin Li, MD, Dong-dong Yan, MD, Zheng Zhang, MD

Abstract

Background: The optimal interventions for unprotected left main coronary artery (ULMCA) disease have long been debated, and long-term clinical studies comparing single stenting to double stenting strategies for ULMCA are currently lacking.

Methods: We plan to perform a systematic review and meta-analysis of clinical trials comparing single stenting with double stents strategy for ULMCA disease. We will search PubMed, EMBASE, Web of science and Cochrane Library using a comprehensive strategy. The related conference proceedings and reference lists of the included studies will also be checked to identify additional studies. Two reviewers will screen retrieved records, extract information and assess the risk of bias independently. STATA software will be used to conduct data synthesis. There is no requirement of ethical approval and informed consent.

Results: This study will be submitted to a peer-reviewed journal for publication.

Conclusion: We hope it will provide a relatively comprehensive reference for clinical practice and future relevant clinical trials.

INPLASY registration number: INPLASY2020110030

Abbreviations: DES = drug-eluting stents, DS = double stents, ST = stent thrombosis, SS = single stent, ULMCA = unprotected left main coronary artery.

Keywords: Unprotected left main coronary artery disease, single and double stenting strategy, drug-eluting stent, long-term clinical outcomes

1. Introduction

Significant left main coronary artery disease occurs in approximately 4% to 6% of patients undergoing coronary angiography.[1] Unprotected left main coronary artery (ULMCA) disease is defined as left main coronary artery disease without right to left collateral circulation or a bridging blood supply.[2] ULMCA is dangerous and presents problem for clinical interventions, meaning the choice of treatment methods is of critical importance. Coronary artery bypass grafting is the recommended gold standard for ULMCA disease.[3] However, with the development of percutaneous coronary intervention techniques and the emergence of drug-eluting stents (DES), percutaneous coronary intervention has emerged as a minimally invasive and therapeutic approach that is comparable to coronary artery bypass grafting intervention.[4,5]

Although the single stent (SS) approach of implanting 1 stent in the main branch is the default intervention strategy for ULMCA lesions, double stents (DS) in which stents are implanted in both the main branch and side branch are employed in patients with severely diseased side branches.[6] High quality meta-analyses has been increasingly regarded as 1 of the key tools for achieving evidence of clinical effectiveness.[7,8] However, only a single meta-analysis[9] published in 2014 compared the outcomes of SS vs DS for ULMCA disease, using odds ratios for their analysis, with no consideration of the effects of time on the outcome. Recent evidence[10,11] has been published that evaluates the reliability of SS vs DS.

Given the paucity of long-term data assessing either strategy, we performed a systematic review and meta-analysis to assessing the long-term effects of SS vs DS interventions for ULMCA disease in the DES era.
2. Methods

2.1. Protocol registration

This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY). The registration number is INPLASY2020110030 (https://inplasy.com/). The content of this protocol will follow the preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) recommendations. We also plan to conduct it in accordance with the Cochrane Handbook for the Systematic Reviews of Interventions and Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines.\(^{[12]}\)

2.2. Eligibility criteria

2.2.1. Types of studies. Clinical trials comparing the SS vs DS strategy for ULMCA disease regardless of the specific stenting technique and side-branch size and lesion complexity.

2.2.2. Types of participants. Patients with ULMCA stenoses treated with second-generation DES.

2.2.3. Types of interventions and comparators. The treatment group will be treated with SS strategy, which is implanting 1 stent in the main branch only. The control group will be treated with DS strategy, which is implanting stents in both the main branch and side branch.

2.2.4. Types of outcome measures. The primary outcomes of interest were major adverse cardiovascular events. Secondary outcomes included all-cause mortality, cardiac mortality, target lesion revascularization, myocardial infarction and stent thrombosis (ST). ST was defined according to the academic research consortium definition.\(^{[13]}\) Major adverse cardiovascular events was defined as the included trials as the composite of death, target lesion revascularization, myocardial infarction, and ST. Besides, all the endpoints reported in the included studies will be collected and evaluated, although we may not mention some of them in this protocol.

2.3. Literature search

A systematic search of online databases including PubMed, EMBASE, Web of science and Cochrane Library will be performed until the end of September 2020 using the keywords “unprotected left main coronary artery disease,” “double stenting strategy” and “drug-eluting stent.” In addition, congress and conference proceedings will be manually retrieved. Related articles and references of included research will also be tracked to find potential studies. If significant data was incomplete in included study, we will contact the authors to get unpublished data.

2.4. Study selection and data extraction

After imported into the Endnote X7 and duplication, retrieved records will be independently screened by 2 reviewers (JJW and XL). Firstly, we will read the titles and abstracts of all identified records to exclude clearly unrelated records based on the inclusion criteria. Then the full texts of the articles retained were reviewed to further determine their suitability. Any disagreement will be resolved by a third reviewer (ZZ). We will show the selection process in details in the PRISMA flow chart.\(^{[14]}\)

Two authors (JJW and XL) of this review will independently extract the data using a pre-defined form. The basic characteristics, related outcome and quality evaluation information of included studies will be collected. Similarly, any discrepancies will be resolved by a third reviewer (ZZ). Data extracted will include author, year, study type, number of participants, intervention, control, population size, patient demographics, procedures, stent type, DS techniques, and outcomes.

2.5. Quality of evidence assessment

The quality of included studies will be assessed by Grading of Recommendations Assessment Development and Evaluation (GRADE), and divided into 4 levels: high quality, moderate quality, low quality, and very low quality.\(^{[15]}\)

2.6. Assessment of study bias

Included study bias will be independently assessed by 2 reviewers (JJW and DDY) and any disagreement will be solved by a third reviewer (ZZ). For randomized controlled trials, we will use the Cochrane risk of bias tools to evaluate potential bias in 7 specific domains:

1. sequence generation,
2. allocation concealment,
3. blinding of participants and personnel,
4. blinding of outcome assessment,
5. incomplete outcome data,
6. selective outcome reporting,
7. other bias.\(^{[16]}\)

For propensity-match cohort studies, 9-star Newcastle-Ottawa Scale will be applied, which rates studies based on 8 criteria in 3 sources of bias.\(^{[17]}\)

2.7. Statistical Analysis

For dichotomous variables, the Hazard Ratios or Odds Ratios with 95% confidence intervals were calculated from each study. Continuous variables will be presented as standard mean difference with 95% confidence intervals. All endpoints will be combined and performed meta-analysis by using DerSimonian and Laird random effects model.\(^{[18]}\) We assessed statistical heterogeneity by using Chi^2 test and I^2 statistic. We will consider significant heterogeneity when P < .10 for Chi^2 or I^2 > 50%.\(^{[19]}\) All primary analyses were performed with STATA v15.1 (Stata Corp, College Station, TX).

2.7.1. Subgroup analysis. We will also conduct subgroup analysis to find more potential information based on pre-set criteria in different follow-up time.

2.7.2. Sensitivity analysis. If the heterogeneity is high, we will conduct sensitivity analyses based on the follow-up time.

2.7.3. Publication bias. The likelihood of publication bias was assessed graphically through the generation of funnel plots, evaluated using an Egger test.\(^{[20]}\)

3. Results

The study does not require ethical approval because the meta-analysis are based on published research and the original data are
4. Discussion

Previous cohort studies have not reached consistent conclusions regarding the clinical outcomes of SS vs DS, and follow-up times varied widely among previous cohort studies. The results from our research may provide meaningful evidence for clinical practice and give a valuable reference for future study.

There seem to be some potential limitations for our study. Firstly, we only include English language articles, which might miss some important data in other language articles. In addition, according to the initial search result, less random controlled trials and more cohort studies will be included in our study, which may have an obstacle to our data pooling and results interpretation. But it probably helps to promotes several more reliable conclusions and focus on more precious direction for future clinical studies to some extent.

Author contributions

JJW and ZZ conceived the idea for this study; JJW and XL designed the meta-analysis; JJW and DDY provided statistical advice and input; JJW and XL drafted the protocol; JJW and DDY reviewed the protocol and provided critical feedback.

Data curation: Jia-jie Wang.
Investigation: Dong-dong Yan.
Methodology: Jia-jie Wang, Xin Li.
Project administration: Jia-jie Wang, zheng zhang.
Software: Xin Li.
Supervision: Dong-dong Yan.
Writing – original draft: Jia-jie Wang, Xin Li.
Writing – review & editing: Dong-dong Yan.

References

[1] Ragosta M. Left main coronary artery disease: Importance, diagnosis, assessment, and management. Curr Prob Cardiology 2015;40:93–126.
[2] Ellis SG, Tamar H, Nobuyoshi M, et al. Contemporary percutaneous treatment of unprotected left main coronary stenoses: Initial results from a multicenter registry analysis 1994-1996. Circulation 1997;96:3867–72.
[3] Levine GN, Bates ER, Blankenship JC, et al. 2011 AHA/ACC/SCAI guideline for percutaneous coronary intervention: a report of the American college of cardiology foundation/American heart association task force on practice guidelines and the society for cardiovascular angiology and interventions. Circulation 2011;124:e574–651.
[4] Beijk MA, Rittersma SZ, Koch KT, et al. Long-term follow-up after nonurgent percutaneous coronary intervention in unprotected left main coronary arteries. Catheter Cardio Inte 2010;75:1026–36.
[5] Ali WE, Vaidya SR, Ejeh SU, et al. Meta-analysis study comparing percutaneous coronary intervention/drug eluting stent versus coronary artery bypass surgery of unprotected left main coronary artery disease: clinical outcomes during short-term versus long-term (> 1 year) follow-up. Medicine (Baltimore) 2018;97:e9909.
[6] Ruhl JH, Santosso T, Kim YH. Which technique for double stenting in unprotected left main bifurcation coronary lesions? Eurointervention 2015;11(Suppl V):V125–8.
[7] Yao L, Sun R, Chen YL, et al. The quality of evidence in chinese meta-analyses needs to be improved. J Clin Epidemiol 2016;74:73–9.
[8] Tian J, Zhang J, Ge L, et al. The methodological and reporting quality of systematic reviews from china and the USA are similar. J Clin Epidemiol 2017;85:50–8.
[9] Karrowni W, Makki N, Dhalwal AS, et al. Single versus double stenting for unprotected left main coronary artery bifurcation lesions: a systematic review and meta-analysis. J Invasive Cardiol 2014;26:229–33.
[10] Kawamoto H, Chieffo A, D’Ascenzo F, et al. Provisional versus elective two-stent strategy for unprotected true left main bifurcation lesions: Insights from a fails-2 sub-study. Int J Cardiol 2018;250:80–5.
[11] Ferenc M, Banholzer N, Hochholzer W, et al. Long-term results after pci of unprotected distal left main coronary artery stenosis: the bifurcations bad krozingen (bbk)-left main registry. Clin Res Cardiol 2018;108:175–84.
[12] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
[13] Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Eng J Med 2007;356:1020–9.
[14] Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analyses: the PRISMA-P 2015: elaboration and explanation. BMJ 2015;350:g7647.
[15] Puhlan MA, Schuernann HJ, Murad MH, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analyses. BMJ 2014;349:g5630.
[16] Corbett MS, Higgins JP, Woolacott NF. Assessing baseline imbalance in randomised trials: implications for the Cochrane risk of bias tool. Res Synth Methods 2014;5:79–85.
[17] Deeks JJ, Dinnes J, D’Amico R, et al. Evaluating non-randomised intervention studies. Health Technol Assess 2003;7:1–73.
[18] DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–88.
[19] Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. Bmj 2003;327:557–60.
[20] Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34.